Gilead Sciences | GILD - Loan Capital


Gilead Sciences reported $20.86B in Loan Capital for its fiscal quarter ending in March of 2026.





Loan Capital Change Date
AbbVie USD 64.53B 5.59B Mar/2026
Agios Pharmaceuticals USD 1.06M 0 Sep/2022
ALKERMES USD 1.48B 7.23M Jun/2026
Alnylam Pharmaceuticals USD 2.47B 6.56M Jun/2026
Amgen USD 51.86B 27M Jun/2026
Biogen USD 7.29B 1B Jun/2026
BioMarin Pharmaceutical USD 3.53B 2.1B Jun/2026
Bristol-Myers Squibb USD 42.09B 59M Jun/2026
Coherus Biosciences USD 51.08M 496K Dec/2025
Eli Lilly USD 47.86B 8.49B Jun/2026
Gilead Sciences USD 20.86B 1.27B Mar/2026
GlaxoSmithKline GBP 13.95B 65M Jun/2026
Glaxosmithkline GBP 18.53B 1.29B Mar/2026
Incyte USD 28.42M 994K Jun/2026
J&J USD 37.34B 183M Jun/2026
Merck USD 51.08B 4.41B Jun/2026
Moderna USD 597M 6M Jun/2026
Neurocrine Biosciences USD 169.5M 500K Mar/2023
Novartis USD 37.49B 42M Jun/2026
Pfizer USD 60.5B 70M Jun/2026
PTC Therapeutics USD 535.52M 248.58M Jun/2026
Puma Biotechnology USD 10.87M 222K Jun/2025
Regeneron Pharmaceuticals USD 1.99B 400K Jun/2026
Sangamo BioSciences USD 0 0 Jun/2022
Sanofi EUR 14.65B 806M Jun/2026
Sarepta Therapeutics USD 847.62M 9.46M Jun/2026
United Therapeutics USD 100M 100M Jun/2024
Vertex Pharmaceuticals USD 106.7M 4.7M Dec/2025